Literature DB >> 26393301

Regulation of Sclerostin Production in Human Male Osteocytes by Androgens: Experimental and Clinical Evidence.

Andrea Di Nisio1, Luca De Toni1, Elena Speltra1, Maria Santa Rocca1, Giuseppe Taglialavoro1, Alberto Ferlin1, Carlo Foresta1.   

Abstract

In this study we aimed to elucidate a possible role of T in the regulation of sclerostin, a glycoprotein secreted by osteocytes known to regulate bone mass. To this end, we evaluated the effect of T stimulation on sclerostin production and gene expression in human cultured osteocytes. In addition, we evaluated serum sclerostin levels in a cohort of 20 hypogonadal male patients, compared with 20 age-matched eugonadal controls. Stimulation with DHT decreased sclerostin expression in cultured osteocytes in a time- and dose-dependent manner. Confirming a direct androgen receptor-mediated effect on sclerostin production, flutamide coincubation and silencing of androgen receptor gene in osteocytes abolished the DHT effects. In addition, hypogonadal patients showed higher serum sclerostin levels with respect to controls (145.87 ± 50.83 pg/mL vs 84.02 ± 32.15 pg/mL; P < .001) and in both probands and controls, serum T levels were negatively correlated with sclerostin (R = -0.664, P = 0.007, and R = -0.447, P = .045, respectively). Finally, multiple stepwise regression analysis showed that T represented the only independent predictor of sclerostin levels. In conclusion, by showing a direct correlation between T and sclerostin, both in vivo and in vitro, this study adds further support to the emerging clinical and experimental studies focusing on sclerostin as a therapeutic target for osteoporosis treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26393301     DOI: 10.1210/en.2015-1244

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.

Authors:  Alberto Ferlin; Luca De Toni; Marco Sandri; Carlo Foresta
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

Review 2.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

Review 3.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

4.  Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment.

Authors:  Ali Shokoohmand; Thomas Kryza; Nathalie Bock; Joan Röhl; Jonelle Meijer; Phong A Tran; Colleen C Nelson; Judith A Clements; Dietmar W Hutmacher
Journal:  Bone Res       Date:  2019-04-25       Impact factor: 13.567

5.  Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen.

Authors:  Mariska C Vlot; Chantal M Wiepjes; Renate T de Jongh; Guy T'Sjoen; Annemieke C Heijboer; Martin den Heijer
Journal:  J Bone Miner Res       Date:  2019-08-19       Impact factor: 6.741

6.  Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice.

Authors:  Haisheng Yang; Alexander Büttner; Laia Albiol; Catherine Julien; Tobias Thiele; Christine Figge; Ina Kramer; Michaela Kneissel; Georg N Duda; Sara Checa; Bettina M Willie
Journal:  Sci Rep       Date:  2020-12-18       Impact factor: 4.379

Review 7.  The Role of Sclerostin in Bone Diseases.

Authors:  Elias S Vasiliadis; Dimitrios-Stergios Evangelopoulos; Angelos Kaspiris; Ioannis S Benetos; Christos Vlachos; Spyros G Pneumaticos
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241

8.  Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days.

Authors:  Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

9.  Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial.

Authors:  Mark Ng Tang Fui; Rudolf Hoermann; Brendan Nolan; Michelle Clarke; Jeffrey D Zajac; Mathis Grossmann
Journal:  Sci Rep       Date:  2018-06-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.